In a nutshell The review aimed to develop recommendations for stopping tyrosine kinase inhibitor (TKI) therapy in patients with chronic myeloid leukemia CML. Some background Tyrosine kinase inhibitors (TKI) are a type of targeted therapy. TKIs have improved the survival outcomes for patients with chronic myeloid...
Read More
In a nutshell This study described real-world outcomes for patients with chronic myeloid leukemia (CML) that started a second-generation tyrosine kinase inhibitor (TKI) therapy and needed to switch to an alternative TKI. The authors concluded that intolerance was the major reason to switch to an alternative TKI and that outcomes were very good...
Read More
In a nutshell This study evaluated the safety and effectiveness of dual chimeric antigen receptor (CAR) T-cell therapy for patients with recurrent or hard-to-treat B-cell non-Hodgkin lymphoma (NHL). This study found that this treatment was safe and effective for these patients. Some background B-cell non-Hodgkin’s lymphoma (NHL) is one of...
Read More
In a nutshell This study aimed to investigate the effect of tyrosine kinase inhibitor (TKI) dose reduction in patients with chronic myeloid leukemia (CML) after achieving a major molecular response (MMR). This study concluded that the TKI dose reduction was safe and effective for the majority of these...
Read More
In a nutshell This study investigated the occurrence of cachexia (CX; weight loss and muscle wasting) in patients with advanced colorectal cancer after first-line therapy. Researchers suggested that CX is present in half of these patients within 24 weeks after starting first-line therapy. Some background Colorectal cancer is the third most common...
Read More
In a nutshell This study looked at the role of circulating tumor DNA (ctDNA) in predicting treatment response in advanced melanoma. They found that in patients treated for the first time with immune treatment, patients with low ctDNA levels had a longer survival without cancer worsening. Some background Advanced melanoma describes melanoma...
Read More
In a nutshell The study evaluated outcomes of anti-programmed cell death-1 monoclonal antibodies (anti-PD-1-mAbs or APMs) before and after allogeneic hematopoietic cell transplantation (alloHCT) for patients with relapsed/refractory Hodgkin lymphoma (r/r-HL). The authors found that patients receiving APMs before alloHCT had frequent immune-related...
Read More
In a nutshell The study evaluated real-life benefits of autologous hematopoietic stem cell transplantation (ASCT) after immune checkpoint inhibitor (CPi) therapy in patients with relapsed/refractory (r/r) Hodgkin lymphoma (HL). The authors found that ASCT can be an effective option after CPi therapy in such patients. Some background Some patients...
Read More
In a nutshell The study compared the long-term effects of moderate hypofractionated intensity-modulated radiation therapy (H-IMRT) and conventionally fractionated IMRT (C-IMRT) on outcomes in patients with localized prostate cancer (PC). The authors found that H-IMRT was similarly effective compared to C-IMRT after 10 years of therapy in such...
Read More
In a nutshell The study evaluated the contribution of chemotherapy on cancer-related cognitive impairment (CRCI) reported by women with early breast cancer. The authors found that chemotherapy added to hormonal therapy caused early and short-term CRCI in such patients, compared to hormonal therapy alone. Some background CRCI refers to problems in...
Read More
In a nutshell This study examined how COVID-19 infection affects patients with cancer undergoing chemotherapy and the role of other factors in COVID-19 complications. The results showed that patients with advanced age and other medical conditions had a higher risk of COVID-19 complications but chemotherapy treatment did not need to be stopped. Some...
Read More
In a nutshell This study examined how COVID-19 infection affects patients with cancer undergoing chemotherapy and the role of other factors in COVID-19 complications. The results showed that patients with advanced age and other medical conditions had a higher risk of COVID-19 complications but chemotherapy treatment did not need to be stopped. Some...
Read More
